PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35000525-11	2022	Our findings indicate that repeated treatments with the rabusertib/olaparib combination result in increased drug resistance and a more aggressive cell phenotype than those with either single agent, providing new clues for future clinical anticancer tests of PARP1 and Chk1 inhibitor combinations.	LY2603618	56-66	poly(ADP-ribose) polymerase 1	Homo sapiens	258-263	
23917378-2	2013	PARP1 inhibitors [AZD2281 ; ABT888 ; NU1025 ; AG014699] interacted with CHK1 inhibitors [UCN-01 ; AZD7762 ; LY2603618] to kill mammary carcinoma cells.	LY2603618	108-117	poly(ADP-ribose) polymerase 1	Homo sapiens	0-5